Six New Ingredients For Japan's NHI List
Six new drug active ingredients in 12 presentations have been added to the National Health Insurance price list by the Japanese Ministry of Health and Welfare, reports Pharma Japan. Five of the six were approved at end-March.
The price of Ono Pharmaceutical's bronchial asthma treatment Onon Cap (pranlukast hydrate) has been given a usefulness premium, while marketability premiums have been granted to Nippon Kayaku for its postmenopausal breast cancer treatment Fareston (toremifene citrate) tabs 40mg and 60mg, Kaken Pharmaceutical's Pronase MS (pronase), used as an in vivo test agent for dissolution of the gastric mucosa in gastric endoscopy (it is already on the NHI list as an anti-inflammatory), and Pharmacia's injectable leukemia treatment Idamycin (idarubicin).
The other products to join the list are Ohta Pharmaceutical's Gaszyme (pronase), with the same indication as Pronase MS, and Nippon Chemiphar's antihypertensive Calvan (bevantolol) tabs 25, 50 and 100mg.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze